Culture-independent microbiological techniques have shown a previously unappreciated complexity to the bacterial microbiome of the respiratory tract that forces reconsideration of the interactions between host, bacteria, and the pathogenesis of exacerbations of chronic lung disease. The composition of the lung microbiome is determined by microbial immigration, elimination, and relative growth rates of its members. All these factors change dramatically in chronic lung disease and further during exacerbations. Exacerbations lack the features of bacterial infections, including increased bacterial burden and decreased diversity of microbial communities. We propose that exacerbations are occasions of respiratory tract dysbiosis-a disorder of the respiratory tract microbial ecosystem with negative eff ects on host biology. Respiratory tract dysbiosis provokes a dysregulated host immune response, which in turn alters growth conditions for microbes in airways, promoting further dysbiosis and perpetuating a cycle of infl ammation and disordered microbiota. Diff erences in the composition of baseline respiratory tract microbiota might help to explain the so-called frequent-exacerbator phenotype observed in several disease states, and might provide novel targets for therapeutic intervention.
Introduction
The natural histories of several chronic lung diseases include exacerbations, which are characterised by abrupt worsening of respiratory symptoms and pulmonary function. Exacerbations cause much of the morbidity, mortality, and expense of chronic lung diseases, 1-3 and are associated with accelerated disease progression. [4] [5] [6] [7] Exacerbations are also associated with viral exposure and bacterial growth in cultures of respiratory specimens, but the precise relation between resident bacteria, acute infection, and the pathogenesis of exacerbations is controversial. 8, 9 In the past decade, new culture-independent techniques for microbial identifi cation such as pyrosequencing have shown a previously unappreciated complexity to the bacterial microbiome in the respiratory tract. 10 The lungs and airways, whether in health or in chronic or acute lung disease, harbour diverse communities of microbes that are undetected by conventional culture-based approaches. A new understanding of lung microbiology has called into question long-held beliefs with respect to the pathogenesis of exacerbations of chronic lung disease derived from a half-century of experimentation and observation using culture-based techniques.
What is an exacerbation?
Exacerbations of chronic lung disease are periods of acute worsening of respiratory symptoms. They arise abruptly, within hours to days, and generally prompt an escalation in therapy. Symptoms might include focal respiratory symptoms, such as cough, increased sputum production, dyspnoea, or wheeze, but might also include systemic features such as fever, fatigue, or malaise. The onset of symptoms often precedes worsening of lung function, 11 although in some patients with impaired perception of the severity of dyspnoea, symptoms are only recognised late in the course of an exacerbation. 12 Exacerbations are typically followed by recovery to a patient's previous lung function, although in many cases patients' lung function returns to a newly compromised baseline. 4, 13 Exacer bations are distinct from primary acute lung infections (such as a lobar pneumonia) and from irreversible progression of underlying lung disease (such as progressively obstructive bronchiolitis obliterans).
Modern techniques to study the lung microbiome
Although a comprehensive discussion of modern techniques would exceed the scope of this review, familiarity with basic principles is key to understanding the revelations and diffi culties in the fi eld. 10, 14, 15 Lung microbiome studies have used various molecular techniques to characterise microbial communities in the respiratory tract, but the most commonly used modern method is high-throughput sequencing of the 16S rRNA gene, a small and highly conserved locus in bacterial DNA. A single sequencing run of a respiratory specimen yields thousands of short DNA sequences. The 16S rRNA
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We searched Medline without date or language restrictions. Initial search phrases were "exacerbation[All Fields] and ("microbiota" [mesh terms] or "microbiota" [all fi elds] or "microbiome" [all fi elds])" an d "disease [all fi elds] and exacerbation [all fi elds] and ("microbiology" [subheading] or "microbiology" [all fi elds] or "bacteria" [all fi elds] or "bacteria" [mesh terms])" where disease represents "cystic fi brosis", "COPD", "bronchiectasis", "asthma", or "pulmonary fi brosis".
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gene also contains hypervariable regions that can provide species-specifi c signature sequences useful for bacterial identifi cation through established gene databases of identifi ed bacterial strains. This method is used to identify com munities of microbes in tissue specimens, enabling analysis of microbial community features such as diversity and the relative membership of bacteria belonging to diff erent taxonomic groups. Quantitative PCR of the 16S rRNA gene provides an approximation of the bacterial burden, which correlates grossly with quantitative results from cultures. 16 Sequencing-based methods do not rely on microbes reproducing in the narrow growth conditions of conventional culture techniques, which fail to identify most human-associated microbes. 17 The type of respiratory specimen studied and its method of acquisition are important factors to consider in interpretation of the results of lung microbiome studies. Many investigators have used bronchoalveolar lavage (BAL) fl uid or protected specimen brushings (PSB). Although passage of a bronchoscope through the upper airways introduces a theoretical risk of con tamination of the lung microbiota from pharyngeal microbiota, 18 the anatomical route of bronchoscope insertion (oral or nasal) has no detectable eff ect on BAL microbiota (appendix). Given the markedly diff erent microbiota in these body sites, 16, 19, 20 the lack of eff ect of bronchoscope insertion demonstrates the minimal eff ect of upper respiratory tract contamination on lung microbiota as detected in BAL fl uid. Additionally, signifi cant associations have been reported between the microbiota of BAL and PSB specimens and several clinical parameters: severity of airway obstruction; 21 airway reactivity; 22 exposure to inhaled medication; 23 disease prognosis; 24 clinical response to therapeutic intervention; 22, 25 and the identity, number, and behaviour of pulmonary infl ammatory cells. 16, 25, 26 Every study using molecular-based culture-independent methods to compare microbiota of healthy people obtained via bronchoscope with that of patients with lung disease has shown substantial diff erences in the composition of the respective bacterial communities. 10 These observations help to validate the biological and clinical relevance of the lung microbiome detected in BAL fl uid and PSB specimens.
For some lung diseases (cystic fi brosis [CF], bronchiectasis, and chronic obstructive pulmonary disease [COPD]), spontaneously expectorated and induced sputum has been used for the analysis of lung microbiota. 10 Although this method introduces a further risk of contamination from upper airway microbiota, 27 features of the microbiota detected in sputum have been signifi cantly associated with patient age, 28 disease severity, 29 airway infl ammation, 21, 30 antibiotic exposure, 31 and response to experimental viral exposure. 30 Thus any noise introduced into sputum specimens from oropharyngeal microbiota does not obscure entirely the meaningful signal from lung microbiota that correlates consistently with other well-established indices of lung health and disease.
The microbial ecology and topology of the human respiratory tract
A key principle in the speciality of microbial ecology is that local environmental conditions determine the composition of microbial communities. An oft-cited tenet in the fi eld is that "Everything is everywhere, but the environment selects." 32 The growth of a species, and its relative abundance in the microbial community, is a function of nutrient availability, temperature, pH, oxygen concentration, and various other environmental factors. Thus any investigation into the respiratory microbiome must take into account the unique local microbial growth conditions of the human respiratory tract, in health and disease, and the dynamics of microbial immigration and elimination.
The airways and alveoli are topologically outside of the body and thus continually exposed to the environment. Although the linear distance from nares to alveolus is only 0·5 m in the average adult, the internal surface area of the lungs is 30 times that of the skin. 33 Each day, this area is exposed to more than 8000 L of inhaled air, carried to the alveolar-capillary interface within 0·1 μm of a tenth of the body's total blood volume. 34 The lungs are arguably the human body's largest and most intimate interface with the external environment. 33, 35 The composition of the lung microbiome is determined by three factors: microbial immigration, microbial elimination and the relative reproduction rates of its
Microbial immigration
Inhalation of bacteria, microaspiration, and direct mucosal dispersion The constituents of the respiratory microbiome are determined by three factors: microbial immigration, microbial elimination, and the relative reproduction rates of its members. Any alteration detected in disease states must be attributable to a combination of any of these three factors. In healthy people, community membership is primarily determined by immigration and elimination of bacteria; in advanced lung disease, community membership is primarily determined by regional growth conditions.
Microbial elimination
See Online for appendix Series members (fi gure 1). 36 Any alteration to the composition of the lung micro biome detected in disease states must be attributable to a combination of these factors. The proportion of the lung microbiome in healthy individuals that comprises resident, reproducing members (subject to regional diff erences in environmental growth conditions) versus transient microbes (determined only by the rates of immigration and elimination) is an area of investigation. 37 Microbes enter the lungs continuously via inhalation of air (containing 10⁴-10⁶ bacterial cells per m³ even before reaching the microbe-dense upper airways 38 ), microaspiration (frequent even in healthy people 39, 40 ) , and direct dispersion along mucosal surfaces. The high degree of shared membership in the oral and lung microbiomes, compared with the air, suggests that microaspiration and direct mucosal dispersion contribute more to microbial immigration than inhalation of bacteria. 37, 41, 42 Microbes are removed from the respiratory tract by mucociliary clearance, cough (frequent even in healthy people 43 ), and the highly active and diverse antimicrobial mechanisms of innate and adaptive immunity. Local microbial growth conditions in the respiratory tract are heterogeneous. In a single lung, large diff erences can be found in oxygen tension, pH, blood perfusion, alveolar ventilation, temperature, epithelial cell structure, deposition of inhaled particles and in the number and behaviour of infl ammatory cells, 36, [44] [45] [46] all of which have eff ects on microbial growth rates. The distal alveoli are bathed in pulmonary surfactant, which has bacteriostatic activity against some (but not all) bacterial species, which creates selective pressure on reproducing microbial com munities. 47 Thus the steady state of the lung microbiome is in fact one of constant infl ux, constant effl ux, and spatial heterogeneity in local microbial growth conditions. Chronic lung disease alters both the topography of the respiratory tract and the dynamics of microbial turnover. Destructive diseases such as emphysema and pulmonary fi brosis substantially reduce the internal surface area of the lungs by as much as 90%. 48, 49 Oesophageal dysfunction and refl ux is extremely common (>70%) in patients with advanced lung disease, and increases the microbial immigration rate and introduces an additional source (gastric) of microbes. 50, 51 Chronic airway diseases such as cystic fi brosis, bronchiectasis, and chronic bronchitis are characterised by impaired mucociliary clearance, which impairs microbial elimination. These diseases are also associated with increased baseline mucus production, which provides a nutrient-rich growth medium for bacteria and pockets of decreased oxygen concentration, 52 and increased temperature. 53 The infl ammatory cells in alveoli and airways are both more numerous and active in chronic lung disease than in health, even in the absence of cigarette smoking or exacerbation of disease. 54, 55 Many therapies for chronic lung disease have eff ects on microbial growth conditions: supplemental oxygen, systemic and inhaled corticosteroids, and systemic and inhaled antibiotics probably all have pleiotropic eff ects on the infl ux, effl ux, and reproduction rates of lung microbiota. As disease severity worsens, the composition of the respiratory microbiome is determined less by the balance of microbial immigration and elimination (the primary determinant in healthy lungs) and more by local growth conditions and diff erential reproduction rates in the respiratory tract, shown by the association between disease severity and the identifi cation of persistent bacterial species (colonisers). [56] [57] [58] In the context of exacerbation of respiratory disease, the topography of the respiratory tract changes further. Hyperventilation accelerates the infl ux of air-borne microbes and markedly decreases airway temperature. 59 Increased cough accelerates microbial effl ux, and the number and activation of infl ammatory cells also increases. 60 Byproducts of the host infl ammatory response such as infl ammatory cytokines, [61] [62] [63] catecholamines, 64 increased temperature, glucose, and free ATP 65 are known growth factors for specifi c bacterial species, which create selectively favourable growth conditions. Bronchoconstriction alters local oxygen concentrations and pH. Acute mucus production and vascular permeability increase local nutrient supply; airway mucus introduces further gradients of local anoxia and hyperthermia, which selectively favour the growth of specifi c lung pathogens. 52, 53, 66, 67 The microbiome and exacerbations of chronic lung diseases COPD Exacerbations of COPD are associated with high mortality, rapid decrease in lung function, and increased health-care costs. 68 Frequency of exacerbations increases with severity of airway obstruction, but many patients experience exacerbations more frequently than would be predicted by disease severity alone (the so-called frequent exacerbator phenotype). 69 Exacerbations are also associated with systemic infl ammation, 70 airway infl ammation, 60 and increased airway obstruction due to oedema, increased sputum production, and bronchoconstriction. 71 A relation between COPD exacerbations and respiratory viral infection is inarguable. In case-control 72 and serially sampled cohort studies, 60, 73 viruses have been identifi ed in respiratory specimens in 39-56% of patients with COPD during exacerbations compared with 6-19% of patients at clinical baseline. 60, 72, 73 When patients with COPD were experimentally infected with rhinovirus, they developed the features of COPD exacerbations (cough, sputum production, airway restriction, and infl ammation) signifi cantly more than did controls without COPD. 74 By contrast, the relation between bacteria and COPD exacerbations has for decades been controversial. Although potentially pathogenic bacteria are cultured from respiratory specimens in 51-70% of patients during Series exacerbations, the same organisms are grown from 25-48% of specimens obtained during clinically stable periods. [75] [76] [77] The culture-determined density of bacteria in sputum is not signifi cantly increased during exacerbation. 78 One hypothesis has attributed exacerbations of COPD to the introduction of new strains of pathogenic bacteria to the airways. One longitudinal study of cultured sputum from outpatients with COPD showed that new strains of bacteria were more frequently isolated during exacerbations than during clinical stability (29% vs 13%); however, more than 70% of exacerbations in patients were not associated with the detection of newly identifi ed bacterial strains. 7 Because of the limitations of the identifi cation of bacterial strains through specimen culture, and a heterogeneous clinical presentation, the relation between bacteria and COPD exacerbations is unclear. 8 The benefi t of antibiotic therapy in the treatment of COPD exacerbations is controversial; recent meta-analyses suggest that anti biotics reduce the frequency of treatment failure in inpatients with severe exacerbations, but are of unclear benefi t for outpatients with mild or moderate disease. 79 A large trial 80 showed reduced frequency of exacerbations in patients receiving chronic azithromycin, which sparked renewed interest in the role that bacteria and host infl ammation have in the pathogenesis of exacerbations.
Recent culture-independent studies have shown an unappreciated complexity of the respiratory microbiota in COPD exacerbations. The airways of patients with exacerbations in fact harbour dozens or hundreds of phylogenetically distinct bacteria, far more than previously appreciated in culture-based studies. Huang and colleagues 81 observed that even in patients who were receiving antibiotics and who were positive for Pseudomonas aeruginosa growth in respiratory cultures, endotracheal aspirate specimens contained hundreds of bacterial species comprising roughly 140 families of bacteria. Subsequent studies have shown comparatively diverse microbial communities in spontaneously expectorated 82 and induced 30 sputum specimens. In all these studies, the bacterial species identifi ed by culture were also identifi ed by culture-independent methods, but the converse is not always the case: community members identifi ed by culture-independent methods are often unidentifi ed by the use of cultures alone.
Exacerbations of COPD are associated with changes in respiratory microbiota and airway infl ammation. Millares and colleagues 82 analysed paired sputum specimens from patients with COPD at baseline and during exacerbations, and found that exacerbations were associated with a selective increase in the relative abundance of bacteria typically associated with exacerbations (eg, Haemophilus, Pseudomonas, and Moraxella) despite inconsistent detection in culture. Huang and colleagues 81 used paired sputum specimens from patients with COPD at baseline and during exacerbation and found a shift in community composition towards the phylum Proteobacteria. Molyneaux and coworkers 30 used a human model of virus-induced COPD exacerbations to systematically compare sputum microbiota in patients at clinical baseline and during exacerbation. Sputum acquired after viral exposure had a substantial shift in bacterial community composition towards the Proteobacteria phylum; this shift was not observed in sputum aquired from healthy controls. None of these three studies showed a decrease in bacterial community diversity, as would be expected in the context of acute infection. 16 Importantly, Molyneaux and colleagues found that bacteria in key taxonomic rankings that spiked in abundance during exacerbation were detected in these same patients both before viral exposure and after clinical resolution of the exacerbation.
Asthma
Exacerbations cause much of the mortality, morbidity, and health-care expenses of asthma.
2,83 Precipitants include allergens, air pollution, and exercise, although, as is the case in COPD, some patients exhibit a frequentexacerbator phenotype independent of other risk factors. 84 Asthma exacerbations are even more strongly associated with viral infections than are the exacerbations of COPD: respiratory viruses (most commonly rhinovirus) are detectable in respiratory specimens from more than 75% of patients with exacerbations, 85 and controlled rhinovirus inoculation provokes the airway hyper-responsiveness observed in allergic asthma. 86 Bacteria have not traditionally been implicated in asthma exacerbations, because they are infrequently cultured from patients' sputum, and trials of antibiotics showed no clinical benefi t. 87 However, recent serology-based and PCR-based approaches have shown a surprising prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae infections in patients with acute exacerbations. 9 Although to date no culture-independent studies have included respiratory specimens obtained from patients with asthma in the context of an exacerbation, several studies have shown that the airways in patients with asthma harbour bacterial microbiota distinct from that of healthy people, suggesting an association between respiratory microbiota, airway infl ammation, and susceptibility to exacerbations. In four separate studies analysing respiratory microbiota (with BAL, 25,88 bronchial brushings, 22, 88 and induced sputum 89 ), the microbiota detected in asthmatic airways at baseline was consistently and substantially diff erent from that of healthy controls. All four studies showed a signifi cant increase in community abundance of Proteobacteria, the phylum that contains common Gram-negative respiratory pathogens such as Haemophilus spp, Pseudomonas spp, and Klebsiella spp. Goleva and colleagues 25 observed an increase in the concentration of lipopolysaccharide in Proteobacteria-enriched specimens, providing in-vivo Series evidence of the diff erence in the community composition of microbiota.
These studies have shown associations between the respiratory microbiome and the clinical, physiological, and therapeutic features of asthma. Huang and colleagues 22 showed that airway hyper-responsiveness (assessed by methacholine challenge) was positively associated with bacterial community diversity and community composition (appendix). This association was driven by the increased abundance of members of the phylum Proteobacteria in patients with hyperresponsive airways. The investigators also showed that clinical improvement with clarithromycin was signifi cantly predicted by diff erences in community diversity in patients' baseline microbiota (appendix). Independently, Goleva and coworkers 25 noted that diff erences in baseline microbiota composition were associated with patients' clinical response to systemic corticosteroids (appendix). In-vitro coculture of macrophages, obtained by BAL, with Haemophilus parainfl uenzae (which the authors observed only in corticosteroid-resistant patients) blunted the response of airway macrophages to the eff ects of corticosteroids, which shows the biological plausibility of a relation between airway microbiota and the hyper-responsiveness that is accentuated during exacerbations.
Cystic fi brosis
Exacerbations of cystic fi brosis are associated with much of the mortality and expense of this diagnosis, and acceleration of decline in lung function.
3, 6 With increasing age, nearly all patients with cystic fi brosis grow specifi c respiratory pathogens from sputum (most commonly Staphylococcus aureus, P aeruginosa, and H parainfl uenzae), 57 both during exacerbations and clinically stable periods. Exacerbations have typically been considered as infectious events and treated primarily with antibiotics, although data supporting this approach are surprisingly sparse. [90] [91] [92] Two large trials have shown no association between patients' response to antibiotic therapy during exacerbations of cystic fi brosis and the in-vitro susceptibility of the cultured respiratory pathogen to the antibiotics administered 93, 94 (fi gure 2A). Furthermore, the clinical course in patients receiving antibiotics during exacerbations is not correlated with changes in bacterial burden in sputum cultures. 95 In the past decade, the use of culture-independent techniques has revolutionised understanding of the respiratory microbiome in cystic fi brosis at clinical baseline and during exacerbations. Early studies revealed far greater microbial community diversity in sputum specimens than was fi rst appreciated with culture, 96 with viability of many microbes verifi ed both via amplifi cation of transcribed RNA 97 and advanced culture techniques. 98 Studies have since confi rmed that the sputum of patients with cystic fi brosis contains diverse bacterial communities, replete both with recognised pathogens and previously unrecognised microbes. 99 Some studies have shown an overall decrease in community diversity with increasing age and disease severity; 10, 28, 29 this loss of diversity is more strongly associated with cumulative antibiotic exposure than disease severity. 29, 31 Culture-independent techniques have overturned longheld assumptions about the bacterial pathogenesis of exacerbations of cystic fi brosis. Several studies have analysed paired specimens obtained from patients during periods of stability and subsequent exacerbation. 29, [100] [101] [102] All have shown remarkably consistent fi ndings: exacerbations of cystic fi brosis are not associated with increased bacterial density or decreased community diversity (fi gure 2B and 2C). These results diff er from those in patients with bacterial pneumonia, in whom, as expected, the bacterial burden is high, bacterial community diversity is low, and the intensity of the host infl ammatory response correlates closely with Series bacterial burden. 16, 103 These fi ndings strongly challenge the conventional understanding of exacerbations of cystic fi brosis as acute infections of the airways.
These same studies have raised the question of whether bacterial community membership changes at the start of an exacerbation, but no consistent pattern of microbial change has emerged. 31 showed that dissimilarity between microbiota at baseline and during exacerbation was signifi cantly associated both with high baseline diversity and baseline community domination by Pseudomonas spp.
Non-cystic fi brosis bronchiectasis
Bronchiectasis that is not attributable to cystic fi brosis can be caused by various predisposing conditions, although most cases are idiopathic. Compared with cystic fi brosis, little is known about the pathophysiology and treatment of the chronic infl ammation and exacerbations that characterise its clinical course. New evidence suggests that chronic macrolide therapy decreases the frequency of exacerbations in patients, 104 although as with cystic fi brosis and COPD, whether this is due to antimicrobial eff ects is unknown.
Several recent studies have used culture-independent analysis to study the microbiome of non-cystic fi brosis bronchiectasis. A study by Tunney and coworkers 19 compared paired sputum and BAL specimens from patients with non-cystic fi brosis bronchiectasis at stability and during exacerbation. They noted no diff erence in bacterial community diversity at the time of exacerbation before the use of antibiotics, and no increase in aerobic, anaerobic or total bacterial growth by a conventional quantitative culture analysis (ie, number of colony forming units). Bacterial communities both at baseline and exacerbation were largely dominated by Proteobacteria (eg Haemophilus spp and Pseudomonas spp). Rogers and colleagues 105 noted that the community membership of sputum microbiota at clinical baseline was predictive of the subsequent frequency of exacerbations; importantly, this association was not detected when limited to culture results alone. A study of explanted lung tissue showed similar microbiota in cystic fi brosis and non-cystic fi brosis bronchiectasis, 106 but how generalisable the fi ndings from cystic fi brosis studies are to patients with non-cystic fi brosis bronchiectasis is unknown.
Idiopathic pulmonary fi brosis (IPF)
Although the natural history of IPF has traditionally been characterised as one of slowly progressive decline in lung function, the existence of acute exacer bations of IPF has been increasingly recognised as a major cause of mortality in this disease. 7 Exacerbations arise over the course of weeks and are characterised by progressive hypoxaemia, lung infi ltrates, the histological presence of diff use alveolar damage, and the clinical exclusion of infection or heart failure. Mortality is high and no therapies have shown benefi t. Many patients with acute exacerbations of IPF have clinical features of infection (fever, cough, and BAL neutrophilia), 107, 108 but no infectious cause has been identifi ed.
Several recent studies have provoked interest in the potential role the bacterial lung microbiome has in the progression of IPF and exacerbations. Richter and others 109 observed a surprisingly high frequency of positive cultures from the BAL specimens in patients with IPF at clinical baseline, and subsequent cultureindependent reports have confi rmed that in IPF the lungs harbour a distinct bacterial microbiome from that of healthy lungs. 24, 110 Han and coworkers 24 reported a positive association between the presence of specifi c microbial community members (Staphylococcus spp and Streptococcus spp) in BAL specimens and disease progression, and investigators of a randomised controlled trial 111 of cotrimoxazole noted reduced mortality in patients with IPF who received antibiotics.
Key lessons and directions for study
Despite the presence of airway infl ammation in respiratory exacerbations, a consistent fi nding across disease states is the lack of evidence that exacerbations are attributable to acute bacterial infections of the airways. Of the eight culture-independent studies across COPD, cystic fi brosis and non-cystic fi brosis bronchiectasis that have compared patients' respiratory specimens obtained at baseline and during exacerbations, all showed no change in the bacterial density or community diversity during exacerbations. 21, 29, 30, 81, 82, [100] [101] [102] This fi nding diff ers from studies of bacterial pneumonia, in which (as expected) increased infl ammation is strongly associated with increases in bacterial burden and decreases in com munity diversity. 36, 103 The airway infl ammation com mon to all exacerbations of respiratory disease is surprisingly dissociated from microbial burden and bacterial community domination by one or a few pathogenic species.
Exacerbations diff er from acute bacterial infections with respect to several factors (table 1). Acute bacterial infections respond rapidly and consistently to antibiotics, whereas data showing benefi t from antibiotics in the treatment of respiratory exacerbations range from minimal to inconsistent to absent. 79, 87, 92 In-vitro tests of the susceptibility of bacteria to antibiotics is clearly of use to predict the response of patients with bacterial lung infections to therapy, 112 but bear no correlation with response to therapy in cystic fi brosis exacerbations. 93, 94 Whereas bacterial lung infections are the most common cause of severe sepsis, 113 exacerbations of respiratory disease rarely (if ever) cause severe sepsis and shock.
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These key diff erences between exacerbations and bacterial infections do not imply that bacteria are uninvolved in exacerbations. Instead, we propose that exacerbations are occasions of respiratory dysbiosis: disorder and dysregulation of the microbial ecosystem of the respiratory tract, coupled with a dysregulated host immune response that results in negative eff ects on host biology. Paired specimen studies have shown substantial changes in the constituents of respiratory bacterial communities during exacerbations, often with large shifts away from Bacteroidetes (the most abundant bacterial phylum in the lungs of healthy people 10, 16, 88 ) and toward Proteobacteria 30, 81, 82 and bacteria belonging to other disease-associated taxonomic ranks.
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The increased frequency of newly isolated strains in cultured sputum specimens from patients with COPD exacerbations compared with baseline (from 13% to 29%) 77 is consistent with the occurrence of respiratory dysbiosis. Altered environ mental conditions might disturb the composition of bacterial communities, increasing the relative abundance of species previously undetectable with culture techniques alone and increasing the community's susceptibility to invasion with new strains.
An analogy can be made between exacerbations of chronic lung disease and exacerbations of infl ammatory bowel disease. Both are defi ned as acute clinical worsening of chronic infl ammatory conditions of mucosa-lined luminal organs, associated with dysbiosis and a dysregulated host infl ammatory response. 114 These diseases are characterised by loss of the homoeostatic balance between resident microbiota and host immunity. 115 Exacerbations in either disease are not caused by an instance of acute infection in which one or a few pathogenic species overtake a body site and directly mediate tissue injury. In both cases, the benefi t of antibiotics, if present, comes not from eradication of a target pathogen but instead from selective manipulation of the composition of the microbial community or indirect immunomodulatory eff ects, which potentially explains the discordance between the sensitivity of bacterial cultures and the clinical response in patients with cystic fi brosis. 93, 94 Exacerbations of both chronic lung disease and infl ammatory bowel disease are preventable or treatable with macrolides that have antimicrobial and immunomodulatory eff ects. 80, 104, 116, 117 We propose a model for the cycle of host infl ammation and respiratory dysbiosis that typifi es an exacerbation of respiratory disease (fi gure 3). An infl ammatory trigger (eg, viral infection or allergic exposure) initiates a cascade of host infl ammatory responses that acutely alters the microbial growth conditions in the airways. Permeability of the airway wall and mucus production provide a nutrient-dense substrate for bacterial growth. 52, 66 Free catecholamines and infl ammatory cytokines (eg, tumour necrosis factor α, interleukins 1, 6, and 8) directly promote the growth of specifi c bacterial species (eg, P aeruginosa, S aureus, S pneumoniae, and Burkholderia cepacia complex). [61] [62] [63] [64] [65] Infl am matory cells are recruited and activated, killing and clearing bacteria with highly variable eff ectiveness, 118 creating selection pressure across species. Airway mucus creates local pockets of increased temperature and decreased oxygen tension, favouring the growth of some disease-associated microbes. 52, 53 In this model, diverse eff ects on microbial growth conditions result in disorder and dysregulation of the dynamic homoeostasis of the airway microbiomeie, respiratory dysbiosis. New and abundant community members, some with altered expression of microbial 
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Bacterial density (compared with baseline) Series virulence proteins or with increased immunogenicity compared with previously abundant members, elicit further airway infl ammation through expression of pathogen-associated molecular patterns, and host pattern recognition receptor interactions, 119 including activation of Toll-like receptors. 120, 121 This infl ammation further alters bacterial growth conditions in the airway, resulting in a positive-feedback cycle. Tissue injury arises from a combination of direct injury by the newly abundant community members, altered microbial behaviour, and indirect eff ects of the dysregulated infl ammatory response. 122 Homoeostasis is achieved only after the positive-feedback cycle of dysbiosis and infl ammation is halted. Although the initial dysbiosis in exacerbations might be secondary to a primary infl ammatory trigger, the relation between infl ammation and respiratory dysbiosis is probably bidirectional and self-perpetuating, providing a plausible explanation for why the airway infl ammation of exacerbations persists long after direct exposure to the infl ammatory precipitant. 13, 30, 68 A distinct but related observation is that the virulence and immunogenicity of a single bacterial species within the respiratory tract is not static, but depends on several host-derived and microbe-derived environmental factors. Published work has shown that the behaviour of a given bacterial strain (as assessed either by gene expression or assays of virulence and immunogenicity proteins) is strongly aff ected by the same environmental factors that diff erentially aff ect bacterial growth rates: temperature, 53, 65 concentration of host-derived cytokines and catecholamines, 63, 64 and presence of free glucose. 65 Furthermore, the behaviour and virulence of one strain is aff ected by the composition of the bacterial community sharing its ecological niche, 123 mediated by direct and indirect microbial interactions. 124, 125 Changes in the metabolism and virulence of microbes (independent of community membership) can modulate infl ammatory cascades, as has been proposed for infl ammatory bowel disease and the gastrointestinal tract, and modelled with P aeruginosa in Drosophilia. 123, 126, 127 Thus the environmental conditions in the airways during infl ammation can aff ect the virulence of individual community members both directly (via the virulence-promoting factors listed above) and indirectly (via the changes in community composition and microbe-microbe interactions in respiratory dysbiosis). This insight is crucial for the future study of bacterial lung disease: the pathogenicity of a species cannot be understood outside of its ecological milieu.
The observation that respiratory exacerbations do not occur in individuals without chronic lung disease is selfevident but telling. The infl ammatory response of healthy airways to an exposure (eg, viral infection) is measured, proportionate to the insult, and self-limiting. Any disruption to the baseline composition of lung microbiota is muted and short-lived. 30 The key features of exacerbations-sustained respiratory dysbiosis coupled with a prolonged immune response disproportionate to the microbial burden-arise only when dysfunction already exists at baseline on both sides of the respiratory microbiome-immune interface. Even when patients are clinically stable (ie, outside of exacerbations), those with chronic lung disease, when compared with healthy people, have alterations to community membership of respiratory microbiota 10, 128 and activation of airway infl ammatory cells 54, 55, 129 (table 2) . The composition of respiratory microbiota, established mainly by the balance of immigration and elimination in health, is increasingly determined by regional growth conditions with increasing severity of lung disease (fi gure 1); during an exacerbation, the eff ect of regional conditions on bacterial growth becomes all-important. We propose that respiratory exacerbations, with their coupled dysbiosis and airway infl ammation, are abrupt, emergent phenomena arising from the chronically disordered but compensated and fragile homoeostasis present in stable chronic lung disease.
An important consequence of understanding the airways as an ecosystem is recognition of the limitations of conventional analytical approaches to modelling its behaviour. Although the conventional model of airway infection suggests linear pathogenesis (a large inoculum of bacteria enters the airways and overwhelms host defences with unrestrained growth and resultant infl ammation), in our model, exacerbations instead emerge abruptly from the complex adaptive system of the respiratory microbiome. 36 Ecosystems have been described as prototypical complex adaptive systems, 130 defi ned by diverse entities interacting with each other in a common space, exhibiting interdependent actions and possessing the capability to adapt to changes in conditions. 131, 132 In linear systems, small changes in conditions result in proportionately small changes in outcomes, whereas in 133, 134 These methods might prove essential to understand how respiratory exacerbations arise from the homoeostasis of clinical stability. 36 The respiratory microbiome might partly explain the so-called frequent-exacerbator phenotype in chronic lung disease. In several chronic lung diseases, a subgroup of patients experience exacerbations more frequently than would be predicted by established risk factors. 69, 84 This frequent-exacerbator phenotype is consistent across years, suggesting a persistent biological predisposition to exacerbations that is unexplained by the current understanding of their pathogenesis. The insights from culture-independent methods have prompted a hypo thesis: diff erences in the composition of baseline respiratory microbiota in terms of species density and diversity might explain the diff erences observed in the frequency of exacerbations in otherwise clinically similar patients.
Several preliminary observations lend support to this hypothesis. Rogers and colleagues 105 showed that in patients with non-cystic fi brosis bronchiectasis, differences in baseline respiratory microbiota were strongly and signifi cantly associated with the number of exacerbations experienced in the subsequent year; importantly, no association was observed between culturebased micro biology results and frequency of exacerbations. Several associations between baseline respiratory microbiota and both airway hyper responsiveness and the clinical response to therapy have been reported for patients with asthma. 22, 25 Molyneaux and others 30 showed that in patients with COPD after rhinovirus exposure, alterations in the respiratory microbiome were heterogeneous in patients and persistent at 6 weeks. Chronic azithromycin therapy has been shown to decrease the frequency of exacer bations in COPD, cystic fi brosis, and non-cystic fi brosis bronchiectasis, 80, 104, 116 although whether this benefi t is attributable to its eff ects on respiratory microbiota is unknown. 135 Two randomised controlled trials 136, 137 have shown benefi t from enteric probiotics in decreasing the frequency of exacerbations of cystic fi brosis. Given the anatomical and ecological continuity of the aerodigestive tract it is possible that this benefi t was mediated partly through changes to the respiratory microbiota. In view of the plausibility of this hypothesis and the high morbidity and health-care costs associated with exacerbations of chronic lung disease, an immediate aim of research should be to determine whether the respiratory microbiome can be used to predict when exacerbations of disease are likely to occur and whether its therapeutic manipulation can decrease the frequency of exacerbations. 128 Culture-based approaches are inadequate to completely understand the interactions of the host, microbiome, and pathogenesis of exacerbations. Studies of respiratory exacerbations that have used both culture-dependent and culture-independent results have shown markedly diff erent results. Culture-independent techniques can confi rm the presence of organisms identifi ed in culture; however, culture-based approaches grossly underestimate the complexity, density, and diversity of respiratory community microbiota. Importantly, culture-independent methods have identifi ed associations between respiratory microbial community features and airway hyperresponsiveness, 22 disease prognosis, 24 susceptibility to exacerbations 105 and the response to experimental viral exposure; 30 these associations would have been unappreciated with culture-based methods. Given the intimate relation between the respiratory microbiome and the host, and the potential role of the microbiome in mediation of acute and chronic infl ammation, changes in the composition of the respiratory microbiome should be considered as a secondary outcome in all clinical trials targeting a reduction in the frequency of exacerbations in chronic lung disease.
